"We think ReCell compares well with these products on a cost and effectiveness standpoint, and that confirmation of results seen to date in venous leg ulcer could potentially lead to $50-100 million in peak revenues. In our previous article on Avita focusing on burns and scalds, we suggested that ReCell could have a $200 million peak revenue opportunity in that indication. Approvals in these indications would clearly be an enormous leap forward for this $40 million market capitalization company."
Very nice. even if only make half the prodiction. Say $100mil a year. That should still give us a market cap around $400mil or 10 times the value of where we are at now.
- Forums
- ASX - By Stock
- AVH
- seekingalpha article on venous ulcers
seekingalpha article on venous ulcers, page-3
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.60 |
Change
0.020(0.78%) |
Mkt cap ! $180.1M |
Open | High | Low | Value | Volume |
$2.59 | $2.63 | $2.56 | $229.1K | 88.76K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $2.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.60 | 18050 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 2.540 |
1 | 2022 | 2.530 |
2 | 9190 | 2.520 |
1 | 1992 | 2.510 |
4 | 16111 | 2.500 |
Price($) | Vol. | No. |
---|---|---|
2.600 | 18050 | 2 |
2.610 | 560 | 1 |
2.620 | 7660 | 2 |
2.630 | 4292 | 3 |
2.640 | 175 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |